Market Cap
$505.8M
ARVN
ARVINAS, INC.
$7.41 ▼ -0.27%
Prev close $7.43Market cap$505.8M
ConsensusHold
12-mo target$13.93 (+88.0%)
▲ Bullish
Analyst conviction 6/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)24 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ARVN right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Buy (57%)
Inst. Holders
50 funds
Inst. Value
$331.8M
Inst. Activity
24 buys / 16 sells
Insider Activity
$268.1K buy / $1.2M sell
Insider Net $
-$903.1K
Social Sentiment
33° Cool
SEC Reports
15
Press Releases
3
Price chart 30d -20.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
Sep 4, 2026 SEC Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage b
Former officer Noah Berkowitz filed Form 144 notices to sell 8,300 shares of Arvinas common stock, valued at approximate
144 — Impact 3/10
Jun 30, 2026 Inst.
Qube Research & Technologies — ADD
1,592,276 shares ($13.2M)
Jun 30, 2026 Inst.
DIMENSIONAL FUND ADVISORS LP — ADD
654,909 shares ($5.4M)
Jun 24, 2026 Insider
Saik Andrew sold 5,696 shares
Chief Financial Officer @ $8.16 ($46.5K)
Jun 24, 2026 Insider
Bain Linda was granted 15,527 shares
Director
Jun 24, 2026 Insider
Jun 23, 2026 SEC Bain Linda was granted 22,714 shares
Director
Arvinas (ARVN) filed an 8-K announcing the departure of Chief Medical Officer Dr. Noah Berkowitz, effective July 3, 2026
8-K — Impact 3/10
Analyst ratings buy % -1.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
57% rate it Buy or better · 23 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 10, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Aug 10, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Aug 5, 2026 | Wells Fargo | DOWNGRADE | Equal-Weight | 54% |
| Aug 5, 2026 | Wedbush | MAINTAIN | Neutral | 57% |
| Aug 4, 2026 | BTIG | REITERATE | Buy | 53% |
| Jun 3, 2026 | Stephens & Co. | REITERATE | Overweight | 54% |
| May 13, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| May 13, 2026 | BTIG | MAINTAIN | Buy | 53% |
| May 4, 2026 | Citigroup | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 9 | 9 | 1 | 0 | 57% | |
| Aug 1, 2026 | 4 | 10 | 8 | 1 | 0 | 61% | |
| Jul 1, 2026 | 5 | 10 | 8 | 1 | 0 | 63% | |
| Jun 1, 2026 | 6 | 10 | 9 | 1 | 0 | 62% | |
| May 1, 2026 | 6 | 10 | 9 | 1 | 0 | 62% | |
| Apr 1, 2026 | 6 | 10 | 9 | 1 | 0 | 62% | |
| Mar 1, 2026 | 6 | 10 | 9 | 1 | 0 | 62% | |
| Feb 1, 2026 | 6 | 10 | 9 | 1 | 0 | 62% |
Price targets
Where 14 covering analysts think ARVN trades over the next 12 months.
$13.93 +88.0% upside Strong Buy
Current$7.41 Low$6.00 Median$13.00 High$21.00 14 analysts
$6.00$21.00
Analyst rating Buy· 2.4/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
33°
Cool
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
15 SEC filing reports analyzed · 3 bullish, 4 bearish, 1 mixed, 7 neutral · avg impact 4.9/10.Plus 3 press releases.
NEUTRAL1443/10
Former officer Noah Berkowitz filed Form 144 notices to sell 8,300 shares of Arvinas common stock, v
Sep 4, 2026
NEUTRAL8-K3/10
Arvinas (ARVN) filed an 8-K announcing the departure of Chief Medical Officer Dr. Noah Berkowitz, ef
Jun 23, 2026
BEARISH8-K6/10
Arvinas announced a pipeline reprioritization, planning to complete the Phase 1 monotherapy dose esc
Jun 5, 2026
MIXED8-K6/10
Arvinas reported Q1 2026 revenue of $15.6M, a 91.7% decline from $188.8M in Q1 2025, driven by the c
May 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs
Sep 29, 2026
other
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company
Sep 29, 2026
Clinical Trial
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Phase Phase 2 — COMPLETED
Sep 28, 2026
other
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –
Sep 3, 2026
other
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.95 | $-1.20–$-0.28 | -97.6% | -1.2% | 5↑ 5↓ | $0.0B | 12 |
| Next Q | $-0.93 | $-1.19–$-0.31 | 15.7% | -2.6% | 5↑ 5↓ | $0.0B | 12 |
| Current FY | $-0.14 | $-0.67–$1.11 | 88.0% | -37.8% | 10↑ 0↓ | $0.3B | 12 |
| Next FY | $-3.23 | $-4.91–$-1.60 | -2259.4% | -5.0% | 5↑ 5↓ | $0.1B | 12 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.948 | — |
| 7d ago | $-0.948 | — |
| 30d ago | $-0.937 | -0.011 |
| 60d ago | $-0.804 | -0.145 |
| 90d ago | $-0.830 | -0.119 |
Institutional ownership
Which big funds own ARVN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $331.8M total value (39,927,631 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, D.. Net buying activity: 24 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 7,609,123 | $63.2M | 19.1% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,123,399 | $34.3M | 10.3% | — |
| D. E. Shaw & Co., Inc. | 3,495,153 | $29.0M | 8.8% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,714,163 | $22.6M | 6.8% | — |
| TWO SIGMA INVESTMENTS, LP | 2,573,447 | $21.4M | 6.4% | — |
| STATE STREET CORP | 2,196,872 | $18.3M | 5.5% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,667,265 | $13.9M | 4.2% | — |
| Qube Research & Technologies Ltd | 1,592,276 | $13.2M | 4.0% | ADD +32.5% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,412,643 | $11.7M | 3.5% | DOUBLED +471.4% |
| FEDERATED HERMES, INC. | 1,356,032 | $11.3M | 3.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | ADD | 1,201,635 | 1,592,276 | +32.5% | $13.2M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 485,764 | 654,909 | +34.8% | $5.4M |
| CITADEL ADVISORS LLC | TRIM | 1,180,988 | 620,973 | -47.4% | $5.2M |
| MORGAN STANLEY | TRIM | 674,718 | 502,755 | -25.5% | $4.2M |
| UBS Group AG | DOUBLED | 68,246 | 444,674 | +551.6% | $3.7M |
| FMR LLC | DOUBLED | 88,232 | 365,206 | +313.9% | $3.0M |
| Jump Financial, LLC | DOUBLED | 133,818 | 296,168 | +121.3% | $2.5M |
| Man Group plc | DOUBLED | 90,969 | 256,104 | +181.5% | $2.1M |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 116,800 | 252,939 | +116.6% | $2.1M |
| Squarepoint Ops LLC | DOUBLED | 23,460 | 201,822 | +760.3% | $1.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 41 transactions. Net -$903.1K — $268.1K bought, $1.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 24, 2026 | Saik Andrew | Chief Financial Officer | SELL | 5,696 | $8.16 | $46.5K |
| Jun 24, 2026 | Bain Linda | Director | AWARD | 15,527 | — | — |
| Jun 24, 2026 | Bain Linda | Director | AWARD | 22,714 | — | — |
| Jun 24, 2026 | Norwalk Leslie V | Director | AWARD | 15,527 | — | — |
| Jun 24, 2026 | Norwalk Leslie V | Director | AWARD | 22,714 | — | — |
| Jun 24, 2026 | Morrison Briggs | Director | AWARD | 15,527 | — | — |
| Jun 24, 2026 | Morrison Briggs | Director | AWARD | 22,714 | — | — |
| Jun 24, 2026 | Kennedy Edward Moore Jr. | Director | AWARD | 15,527 | — | — |
| Jun 24, 2026 | Kennedy Edward Moore Jr. | Director | AWARD | 22,714 | — | — |
| Jun 24, 2026 | Smaldone Alsup Laurie | Director | AWARD | 22,714 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ARVN.
Shares short
4,986,181
Settlement Sep 15, 2026
Change vs prior
+5.8%
Semi-monthly cycle
Days to cover
5.6
At avg daily volume
Of shares outstanding
≈7.6%
Estimate — not % of float
All ARVN filing & press-release reports (18)
- 144 reportSep 4, 2026
- 8-K reportJun 23, 2026
- 8-K reportJun 5, 2026
- 8-K reportMay 12, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- 144 reportMay 8, 2026
- 144 reportMay 8, 2026
- PRESS-RELEASE reportMay 5, 2026
- 8-K reportMay 1, 2026
- PRESS-RELEASE reportMay 1, 2026
- DEFA14A reportApr 29, 2026
- 8-K reportMar 18, 2026
- PRESS-RELEASE reportMar 18, 2026
- PRESS-RELEASE reportMar 11, 2026
- CLUSTER reportMar 9, 2026
- CLUSTER reportMar 3, 2026
- CLUSTER reportFeb 26, 2026